Abstract
3 controlled cohorts of mass-screening for colorectal cancer using a biennial faecal occult blood (HemoccultII®) test on well-defined European populations have demonstrated a 14% to 18% reduction in specific mortality. We aimed to estimate the sensitivity (S) of this HemoccultII® test and and also mean sojourn time (MST) from French colorectal mass-screening programme data. 6 biennial screening rounds were performed from 1988 to 1998 in 45 603 individuals aged 45–74 years in Saône-et-Loire (Burgundy, France). The prevalent/incidence ratio was calculated in order to obtain a direct estimate of the product S.MST. The analysis of the proportional incidence and its modelling was used to derive an indirect estimate of S and MST. The product S.MST was higher for males than females and higher for left colon than either the right colon or rectum. The analysis of the proportional incidence confirmed the result for subsites but no other significant differences were found. The sensitivity was estimated at 0.57 and the MST at 2.56 years. This study confirms that the sensitivity of the Hemoccult test is relatively low and that the relatively short sojourn time is in favour of annual screening. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Day NE (1985) Estimating the sensitivity of a screening test. J Epidemiol Commun Health 39: 364–366
Day NE and Walter SD (1984) Simplified models of screening for chronic disease from mass screening programmes. Biometrics 40: 1–14
European Group for Colorectal Cancer Screening (1999) Recommandation to include colorectal cancer screening in public health policy. J Med Screen 6: 80–81
Faivre J, Tazi MA, Milan C, Lejeune C, Dassonville F and Durand G (1999) L'étude bourguignonne d'évaluation du dépistage de masse du cancer colorectal par la recherche d'un saignement occulte dans les selles: résultats à 9 ans. Gastroenterol Clin Biol 23: A88
Gyrd-Hansen D, Søgaard J and Kronborg O (1997) Analysis of screening data: colorectal cancer. Int J Epidemiol 26: 1172–1181
Hardcastle JD, Chamberlain JO, Robinson MHE, Moss SM, Amar SA, Balfour TW, James PD and Mangham CM (1996) Randomized controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348: 1472–1477
Kronborg O, Fenger C, Olsen J, Dan Jørgensen O and Søndergaard O (1996) Randomized study as screening for colorectal cancer with faecal-occult-blood test. Lancet 348: 1467–1471
Launoy G, Smith TC, Duffy SW and Bouvier V (1997) Colorectal cancer mass-screening: estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time. Int J Cancer 73: 220–224
Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM and Ederer F (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328: 1365–1371
Moss SM, Hardcastle JD, Coleman DA, Robinson MHE and Rodrigues VC (1999) Interval cancers in a randomized controlled trial of screening for colorectal cancer using a faecal occult blood test. Int J Epidemiol 28: 386–390
Paci E and Duffy SW (1991) Modelling the analysis of breast cancer screening programme: Sensitivity, Lead Time and Predictive Value in the Florence District Programme (1975–1986). Int J Epidemiol 20: 4852–4858
Tazi MA, Faivre J, Dassonville F, Lamour J, Milan C and Durand G (1997) Participation in faecal occult blood screening for colorectal cancer in a well defined French population: results of five screening rounds from 1988 to 1996. J Med Screen 4: 147–151
Towler BP, Irwig L, Glasziou P, Weller D and Kewenter J (2000) Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2: CD001216
Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH and Panish JF (1993) The National Polyp Study Workgroup. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 329: 1977–1981
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Jouve, J., Remontet, L., Dancourt, V. et al. Estimation of screening test (Hemoccult®) sensitivity in colorectal cancer mass screening. Br J Cancer 84, 1477–1481 (2001). https://doi.org/10.1054/bjoc.2001.1752
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1752
Keywords
This article is cited by
-
Contribution of the OC Sensor® immunoassay in comparison to the Hemoccult II® guaiac-test in organized colorectal cancer screening
European Journal of Epidemiology (2019)
-
Predictors of Colorectal Cancer After Negative Colonoscopy: A Population-Based Study
American Journal of Gastroenterology (2010)
-
Rate and Predictors of Early/Missed Colorectal Cancers After Colonoscopy in Manitoba: A Population-Based Study
American Journal of Gastroenterology (2010)
-
Du dépistage au diagnostic des cancers en 2010
Oncologie (2010)
-
Sensitivity of latex agglutination faecal occult blood test in the Florence District population-based colorectal cancer screening programme
British Journal of Cancer (2007)